Sigma-Aldrich Corp (SIAL) 137.16 $SIAL
Sigma-Aldrich Buyout by Merck KGaA Gets Antitrust Clearance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 8:30AM CST
Sigma-Aldrich Corporation (SIAL) and Merck KGaA (MKGAY) announced that latter has obtained antitrust clearance from the US FTC for its previously announced acquisition of Sigma-Aldrich.
ROC: 79.11 (-0.01), SIAL: 137.16 (-0.01), MTX: 71.84 (+0.11)
Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance
PR Newswire - Tue Dec 23, 8:44AM CST
Sigma-Aldrich Corporation (NASDAQ: SIAL) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in connection with the acquisition expired on December 22, 2014, thereby completing the U.S. HSR Act antitrust notification and review requirement for the acquisition of the Company by Merck KGaA, Darmstadt, Germany.
SIAL: 137.16 (-0.01)
Sigma-Aldrich Up 43.7% Since SmarTrend Uptrend Call (SIAL)
Comtex SmarTrend(R) - Fri Dec 19, 4:49PM CST
SmarTrend identified an Uptrend for Sigma-Aldrich (NASDAQ:SIAL) on April 2nd, 2014 at $95.00. In approximately 9 months, Sigma-Aldrich has returned 43.69% as of today's recent price of $136.51.
SIAL: 137.16 (-0.01)
Today's Strong And Under The Radar Stock Is Sigma-Aldrich (SIAL)
at The Street - Wed Dec 17, 9:15AM CST
Trade-Ideas LLC identified Sigma-Aldrich (SIAL) as a strong and under the radar candidate
SIAL: 137.16 (-0.01)
Sigma-Aldrich (SIAL) Breaks Through Resistance at $136.40
Comtex SmarTrend(R) - Wed Dec 17, 9:01AM CST
Shares of Sigma-Aldrich (NASDAQ:SIAL) opened today above their pivot of $136.15 and have already reached the first level of resistance at $136.40. Should the shares continue to rise, the resistance pivots of $136.69 and $137.23 will be of interest.
SIAL: 137.16 (-0.01)
The Best Of The Best: Top 7 Dividend Aristocrats
Sure Dividend - at Seeking Alpha - Mon Dec 15, 6:55PM CST
Over the past 3 months I have analyzed each of the 54 Dividend Aristocrats. The complete list of Dividend Aristocrats sorted by sector is included in the tables below: Basic Materials Consumer Goods Financials Health Care ...
MKC: 76.63 (-0.15), GPC: 107.62 (-0.21), CAH: 82.07 (+0.15), ED: 66.91 (+0.90), SYY: 40.59 (-0.11), WMT: 86.43 (-0.23), GWW: 256.98 (-0.82), PNR: 66.99 (-0.09), TGT: 74.65 (-0.04), ABBV: 66.21 (+1.86), LOW: 67.51 (-0.43), BCR: 169.10 (-0.44), TROW: 87.34 (-0.25), VFC: 74.63 (-0.01), FDO: 79.14 (-0.01), HRL: 53.08 (-0.17), MHFI: 90.70 (+0.34), ADP: 85.24 (+0.07), ADM: 53.11 (-0.06), SIAL: 137.16 (-0.01), MCD: 93.83 (-0.39), DOV: 74.20 (-0.28), CVX: 113.47 (-0.48), SHW: 264.55 (+1.46), BF.B: 90.41 (+0.40), MMM: 166.96 (+0.09), BDX: 139.90 (+1.44), CLX: 105.46 (-0.62), MDT: 74.08 (+0.31), KMB: 117.77 (-0.21), XOM: 93.78 (-0.81), CB: 104.37 (-0.07), PEP: 97.09 (-0.27), SWK: 97.36 (+0.04), JNJ: 104.59 (+0.31), T: 33.96 (-0.07), CINF: 52.18 (-0.19), PPG: 231.12 (+0.05), WAG: 76.67 (+0.16), APD: 148.58 (unch), ECL: 107.18 (-0.27), KO: 42.94 (-0.03), ABT: 45.70 (-0.02), HCP: 44.00 (-0.45), NUE: 49.33 (-0.22), EMR: 62.73 (-0.10), LEG: 42.40 (+0.19), BMS: 45.96 (-0.12), ITW: 97.11 (-0.10), CTAS: 79.86 (+0.22), PG: 93.14 (-0.15), BEN: 56.99 (-0.14), AFL: 61.94 (unch), CL: 70.47 (-0.53)
United States Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry Analytics 2014-2021 - Market to reach $21.2 billion by 2021
M2 - Mon Dec 15, 8:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/b7xlml/vitamins) has announced the addition of Plunkett Research Ltd's new report "Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry (U.S.) to reach $21.2 billion by 2021. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies - Aceto Corporation - Balchem Corp - Cambrex Corp - Mannatech Inc - Mead Johnson Nutrition Company - NBTY Inc - Schiff Nutrition International Inc - Sigma-Aldrich Corp - Synutra International, Inc. - USANA Health Sciences Inc For more information visit http://www.researchandmarkets.com/research/b7xlml/vitamins Source: Plunkett Research Ltd
ACET: 21.85 (-0.07), MJN: 102.04 (+0.48), CBM: 21.62 (+0.37), SIAL: 137.16 (-0.01), USNA: 103.51 (+0.91), SYUT: 5.20 (+0.07), MTEX: 28.96 (unch), BCPC: 66.80 (-1.55)
Sigma-Aldrich Shares Up 43.3% Since SmarTrend's Buy Recommendation (SIAL)
Comtex SmarTrend(R) - Fri Dec 12, 11:11AM CST
SmarTrend identified an Uptrend for Sigma-Aldrich (NASDAQ:SIAL) on April 2nd, 2014 at $95.00. In approximately 8 months, Sigma-Aldrich has returned 43.28% as of today's recent price of $136.12.
SIAL: 137.16 (-0.01)
Survey of Academic Translational Researchers Highlights Challenges to Reproducible Science
PR Newswire - Thu Dec 11, 6:00AM CST
Sigma-Aldrich Corporation (NASDAQ: SIAL) today issued the second annual State of Translational Research Survey Report, addressing challenges to the reproducibility of research within the academic translational research community. Sigma-Aldrich's report, based on a survey conducted in concert with the Association for the Advancement of Science (AAAS) and the Academic Drug Discovery Consortium (ADDC), sheds light on practices that compromise the reproducibility of published research, underlines the translational research community's desire for experimental standards, and suggests multi-faceted strategies for improving the reproducibility of translational science.
SIAL: 137.16 (-0.01)
Research and Markets: Global Cellular Imaging Markets Report 2014
Business Wire - Wed Dec 10, 3:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/r8ggbl/cellular_imaging) has announced the addition of the "Global Cellular Imaging Markets Report 2014" report to their offering.
A: 41.13 (-0.24), SIAL: 137.16 (-0.01), DHR: 86.79 (-0.27)
Global Cellular Imaging Markets Report 2014
M2 - Wed Dec 10, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/tj5773/cellular_imaging) has announced the addition of the "Global Cellular Imaging Markets Report 2014" report to their offering. The Global Cellular Imaging Market is dominated by Beckton Dickinson and Company, Danaher Corporation, Sigma-Aldrich Corporation, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., GE Healthcare, Merck KGAA, Olympus Corpopration, Perkinelmer, Inc., Promega Corporation. The global cell analysis market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Most of the players in the cell analysis instruments market are collaborating with companies and educational institutes in order to offer the products with better software also. The cell analysis market is expected to grow steadily in the forecast period. The major factor driving the growth is improved accuracy of cell imaging and analysis systems which in turn reduce time and cost of drug discovery process. In addition, the factors like increasing prevalence of cancer, getting help from the government bodies in the form of investments, funds and grants, improved informatics services, availability of better reagents and image analysis instruments are propelling the growth of the market. However, the major market restraints include enormous capital investments and shortage of skilled labor for high content screening procedure. The biggest opportunities for this market is the growing APAC market, high content screening services provided by CRO's, automation in cancer research for its early detection and reducing cost of the cancer treatment. Key Topics Covered: 1. Executive summary 2. Introduction 3. Market Analysis 4. Single cell analysis market by technology 5. Single cell analysis market by products 6. Single cell analysis market by field of study 7. Single cell analysis market by applications 8. Single cell analysis market by end users 9. Regional Market Analysis 10. Company Developments 11. Major Company Profiles - Agilent Technologies, Inc. - Beckton, Dickinson And Company - Danaher Corporation - GE Healthcare - Merck KGaA - Olympus Corpopration - Perkinelmer, Inc - Promega Corporation - Sigma-Aldrich Corporation - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/tj...ar_imaging
A: 41.13 (-0.24), SIAL: 137.16 (-0.01), DHR: 86.79 (-0.27)
Sigma-Aldrich Shareholders Clears Takeover by Merck KGaA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 11:40AM CST
Sigma-Aldrich's (SIAL) shareholders have approved its proposed acquisition by Germany's Merck KGaA for $17 billion.
ROC: 79.11 (-0.01), NL: 8.72 (+0.14), SIAL: 137.16 (-0.01), MTX: 71.84 (+0.11)
Sigma-Aldrich® Again Named Top Company for Strengthening Communities through Science
PR Newswire - Mon Dec 08, 7:30AM CST
Sigma-Aldrich Corporation (Nasdaq: SIAL) was named today to The Civic 50, an annual initiative that recognizes leading community-minded companies in the U.S. Conducted by Points of Light, the largest organization in the world dedicated to volunteer service, and supported by Bloomberg LP, The Civic 50 honors forward-thinking businesses that are strengthening their communities and demonstrating a correlation between civic engagement and overall bottom-line benefits.
SIAL: 137.16 (-0.01)
Sigma-Aldrich's stockholders grants approval for its USD140/share acquisition by Merck KGaA
M2 - Mon Dec 08, 6:59AM CST
Sigma-Aldrich (NASDAQ:SIAL) said on Friday that its stockholders have voted to adopt the merger agreement with and into Merck KGaA, Darmstadt, Germany at a special meeting of stockholders held earlier today.
SIAL: 137.16 (-0.01)
Global Glycobiology/Glycomics Market 2014-2019: Enzymes, Instruments, Kits, and Reagents
M2 - Mon Dec 08, 3:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/sj4p7d/glycobiologyglyco) has announced the addition of the "Glycobiology/Glycomics Market by Product, Application & by End User - Global Forecast to 2019" report to their offering. The key drivers for this market are the rising R&D expenditure by pharmaceutical and biotech companies, and increasing public and private funding for proteomics and glycomics research. According to the World Bank, funding for research and development activities in Asia was about $158.94 billion in 2001 and increased to $329.31 billion in 2010. Similarly, in the U.S., overall funding for research and development was about $291.77 billion in 2001, which increased to $428.94 billion in 2010. Increased funding activities are expected to positively impact the growth of the glycomics enzymes, instruments, kits, and reagents market. This report segment the global glycomics market by application, end users, products, and geographies. The application segments included in this report are diagnostics; drug discovery and development; immunology; oncology; and other applications. The end-user segments of this market are academic research institutes, contract research organizations, and pharmaceutical and biotechnology companies. The product segments included in this report are enzymes; instruments; kits; and reagents. Glycosidases; glycosyltransferases; neuraminidases; sialyltransferases; and other enzymes are subsegments of the enzymes product segment. Antibody arrays; HPLC; lectin arrays; MALDI-TOF; mass spectrometers; and other glycomics instruments are subsegments of the instruments product segment. Glycan labeling kits; glycan purification kits; glycan release kits; and other glycomics kits are subsegments of the kits market. Glycoproteins; monosaccharaides; oligosaccharides; and other glycomics reagents are subsegments of the reagents product segment. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Glycomics Market, By Product 8 Glycomics Market, By Application 9 Glycomics Market, By End User 10 Geographic Analysis 11 Competitive Landscape 12 Company Profiles - Agilent Technologies, Inc. - Bruker Corporation - Danaher Corporation - New England Biolabs - Prozyme - Shimadzu Corporation - Sigma-Aldrich Corporation - Takara Bio - Thermo Fisher Scientific - Waters Corporation For more information visit http://www.researchandmarkets.com/research/sj...ologyglyco
A: 41.13 (-0.24), SIAL: 137.16 (-0.01), DHR: 86.79 (-0.27), WAT: 114.54 (+0.21)
Sigma-Aldrich Stockholders Approve Acquisition By Merck KGaA
PR Newswire - Fri Dec 05, 11:30AM CST
Sigma-Aldrich Corporation (NASDAQ: SIAL) stockholders voted to adopt the previously announced merger agreement providing for the acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany at a special meeting of stockholders held earlier today. Sigma-Aldrich stockholders also approved, on an advisory, non-binding basis, compensation that may become payable to named executive officers as a result of the acquisition.
SIAL: 137.16 (-0.01)
Laboratory Filtration Market 2014-2019 - Global Technology, Product, Accessories & End-User Forecasts for the $2.5 Billion Market
M2 - Fri Dec 05, 3:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/hmsvk6/laboratory) has announced the addition of the "Laboratory Filtration Market by Technology, Product, Accessories & by End-User - Global Forecasts to 2019" report to their offering. The global laboratory filtration market is expected to grow at a strong CAGR during the forecast period of 2014-2019 and is estimated to be worth $2,532.6 million by 2019. The market is mainly driven by the increasing research activities in the pharmaceutical and biotechnology segments, and growing demand for biotech molecules for therapeutic and diagnostic applications and increasing purity requirements in end-user markets. However, technological developments cutting down the use of the membrane filtration technology may hamper the growth of the market to a certain extent. During the forecast period the microfiltration segment will continue to dominate the laboratory filtration market. Microfiltration segment is growing primarily due to increasing use of microfiltration membranes as prefilters to ultrafiltration and reverse osmosis processes. Furthermore, growing demand of filtration technologies in pharmaceutical and biopharmaceutical industries is also expected to drive the growth of the laboratory filtration market. By 2019, North America will be the largest share to the global laboratory filtration market, followed by Europe, Asia-Pacific, and RoW. Developed markets like North America and Europe are likely to grow at a lower CAGR as compared to the Asia-Pacific market. The Asia Pacific region is expected to have the fastest market growth during the forecast period, largely driven by the increasing research funding form government and private investors and growing number of research laboratories. The major players in the laboratory filtration market include The major players in the laboratory filtration market include Pall Corporation (U.S.), Merck Millipore (Germany), GE Healthcare (U.S.), Sartorius Group (Germany), 3M Purification (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Cantel Medical Corp. (U.S.), and Sigma Aldrich (U.S.). Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Global Laboratory Filtration Market, By Technology 8 Global Laboratory Filtration Equipment Market, By Type 9 Global Lab Filtration Accessories Market, By Type 10 Global Laboratory Filtration Market, By End User 11 Laboratory Filtration Market, By Geography 12 Competitive Landscape 13 Company Profiles - 3M Company - Cantel Medical Corp. - General Electric Company - Merck Millipore - Pall Corporation - Sartorius Group - Sigma-Aldrich Corporation - Sterlitech Corporation - Thermo Fisher Scientific, Inc. - Veolia Water Technologies Corporation For more information visit http://www.researchandmarkets.com/research/hmsvk6/laboratory
MMM: 166.96 (+0.09), GE: 25.83 (-0.05), PLL: 101.86 (+0.70), SIAL: 137.16 (-0.01), MRK: 57.46 (+0.25), CMN: 42.07 (+0.40)
Sigma-Aldrich Life Sciences Licenses Foundational CRISPR Patents from Broad Institute
PR Newswire - Thu Dec 04, 6:00AM CST
Sigma-Aldrich® Corporation (NASDAQ: SIAL), today announced that Sigma® Life Science, its innovative biological products and services business, has entered into a non-exclusive agreement for the use of CRISPR/Cas technology covered under patents held by the Broad Institute of MIT and Harvard. Under the agreement, Sigma-Aldrich is able to make, use and distribute the advanced gene editing tools for numerous research applications, including the generation of modified plant and animal models, custom cell line creation and for CRISPR/Cas arrayed and pooled genetic screening.
SIAL: 137.16 (-0.01)
Sigma-Aldrich Introduces Certified Reference Materials - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 10:40AM CST
Sigma-Aldrich Corporation (SIAL) announced that the Cerilliant brand, within its Applied Diagnostics and Testing division, has launched new solution-based Certified Reference Materials (CRMs) of seven Cannabis biomarkers.
NL: 8.72 (+0.14), SIAL: 137.16 (-0.01), TAM: 26.00 (+0.01), MTX: 71.84 (+0.11)
Sigma-Aldrich Buyout by Merck KGaA Gets Antitrust Clearance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 8:30AM CST
Sigma-Aldrich Corporation (SIAL) and Merck KGaA (MKGAY) announced that latter has obtained antitrust clearance from the US FTC for its previously announced acquisition of Sigma-Aldrich.
ROC: 79.11 (-0.01), SIAL: 137.16 (-0.01), MTX: 71.84 (+0.11)
Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance
PR Newswire - Tue Dec 23, 8:44AM CST
Sigma-Aldrich Corporation (NASDAQ: SIAL) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in connection with the acquisition expired on December 22, 2014, thereby completing the U.S. HSR Act antitrust notification and review requirement for the acquisition of the Company by Merck KGaA, Darmstadt, Germany.
SIAL: 137.16 (-0.01)
Sigma-Aldrich Up 43.7% Since SmarTrend Uptrend Call (SIAL)
Comtex SmarTrend(R) - Fri Dec 19, 4:49PM CST
SmarTrend identified an Uptrend for Sigma-Aldrich (NASDAQ:SIAL) on April 2nd, 2014 at $95.00. In approximately 9 months, Sigma-Aldrich has returned 43.69% as of today's recent price of $136.51.
SIAL: 137.16 (-0.01)
Today's Strong And Under The Radar Stock Is Sigma-Aldrich (SIAL)
at The Street - Wed Dec 17, 9:15AM CST
Trade-Ideas LLC identified Sigma-Aldrich (SIAL) as a strong and under the radar candidate
SIAL: 137.16 (-0.01)
Sigma-Aldrich (SIAL) Breaks Through Resistance at $136.40
Comtex SmarTrend(R) - Wed Dec 17, 9:01AM CST
Shares of Sigma-Aldrich (NASDAQ:SIAL) opened today above their pivot of $136.15 and have already reached the first level of resistance at $136.40. Should the shares continue to rise, the resistance pivots of $136.69 and $137.23 will be of interest.
SIAL: 137.16 (-0.01)
The Best Of The Best: Top 7 Dividend Aristocrats
Sure Dividend - at Seeking Alpha - Mon Dec 15, 6:55PM CST
Over the past 3 months I have analyzed each of the 54 Dividend Aristocrats. The complete list of Dividend Aristocrats sorted by sector is included in the tables below: Basic Materials Consumer Goods Financials Health Care ...
MKC: 76.63 (-0.15), GPC: 107.62 (-0.21), CAH: 82.07 (+0.15), ED: 66.91 (+0.90), SYY: 40.59 (-0.11), WMT: 86.43 (-0.23), GWW: 256.98 (-0.82), PNR: 66.99 (-0.09), TGT: 74.65 (-0.04), ABBV: 66.21 (+1.86), LOW: 67.51 (-0.43), BCR: 169.10 (-0.44), TROW: 87.34 (-0.25), VFC: 74.63 (-0.01), FDO: 79.14 (-0.01), HRL: 53.08 (-0.17), MHFI: 90.70 (+0.34), ADP: 85.24 (+0.07), ADM: 53.11 (-0.06), SIAL: 137.16 (-0.01), MCD: 93.83 (-0.39), DOV: 74.20 (-0.28), CVX: 113.47 (-0.48), SHW: 264.55 (+1.46), BF.B: 90.41 (+0.40), MMM: 166.96 (+0.09), BDX: 139.90 (+1.44), CLX: 105.46 (-0.62), MDT: 74.08 (+0.31), KMB: 117.77 (-0.21), XOM: 93.78 (-0.81), CB: 104.37 (-0.07), PEP: 97.09 (-0.27), SWK: 97.36 (+0.04), JNJ: 104.59 (+0.31), T: 33.96 (-0.07), CINF: 52.18 (-0.19), PPG: 231.12 (+0.05), WAG: 76.67 (+0.16), APD: 148.58 (unch), ECL: 107.18 (-0.27), KO: 42.94 (-0.03), ABT: 45.70 (-0.02), HCP: 44.00 (-0.45), NUE: 49.33 (-0.22), EMR: 62.73 (-0.10), LEG: 42.40 (+0.19), BMS: 45.96 (-0.12), ITW: 97.11 (-0.10), CTAS: 79.86 (+0.22), PG: 93.14 (-0.15), BEN: 56.99 (-0.14), AFL: 61.94 (unch), CL: 70.47 (-0.53)
United States Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry Analytics 2014-2021 - Market to reach $21.2 billion by 2021
M2 - Mon Dec 15, 8:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/b7xlml/vitamins) has announced the addition of Plunkett Research Ltd's new report "Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry (U.S.) to reach $21.2 billion by 2021. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies - Aceto Corporation - Balchem Corp - Cambrex Corp - Mannatech Inc - Mead Johnson Nutrition Company - NBTY Inc - Schiff Nutrition International Inc - Sigma-Aldrich Corp - Synutra International, Inc. - USANA Health Sciences Inc For more information visit http://www.researchandmarkets.com/research/b7xlml/vitamins Source: Plunkett Research Ltd
ACET: 21.85 (-0.07), MJN: 102.04 (+0.48), CBM: 21.62 (+0.37), SIAL: 137.16 (-0.01), USNA: 103.51 (+0.91), SYUT: 5.20 (+0.07), MTEX: 28.96 (unch), BCPC: 66.80 (-1.55)
Sigma-Aldrich Shares Up 43.3% Since SmarTrend's Buy Recommendation (SIAL)
Comtex SmarTrend(R) - Fri Dec 12, 11:11AM CST
SmarTrend identified an Uptrend for Sigma-Aldrich (NASDAQ:SIAL) on April 2nd, 2014 at $95.00. In approximately 8 months, Sigma-Aldrich has returned 43.28% as of today's recent price of $136.12.
SIAL: 137.16 (-0.01)
Survey of Academic Translational Researchers Highlights Challenges to Reproducible Science
PR Newswire - Thu Dec 11, 6:00AM CST
Sigma-Aldrich Corporation (NASDAQ: SIAL) today issued the second annual State of Translational Research Survey Report, addressing challenges to the reproducibility of research within the academic translational research community. Sigma-Aldrich's report, based on a survey conducted in concert with the Association for the Advancement of Science (AAAS) and the Academic Drug Discovery Consortium (ADDC), sheds light on practices that compromise the reproducibility of published research, underlines the translational research community's desire for experimental standards, and suggests multi-faceted strategies for improving the reproducibility of translational science.
SIAL: 137.16 (-0.01)
Research and Markets: Global Cellular Imaging Markets Report 2014
Business Wire - Wed Dec 10, 3:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/r8ggbl/cellular_imaging) has announced the addition of the "Global Cellular Imaging Markets Report 2014" report to their offering.
A: 41.13 (-0.24), SIAL: 137.16 (-0.01), DHR: 86.79 (-0.27)
Global Cellular Imaging Markets Report 2014
M2 - Wed Dec 10, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/tj5773/cellular_imaging) has announced the addition of the "Global Cellular Imaging Markets Report 2014" report to their offering. The Global Cellular Imaging Market is dominated by Beckton Dickinson and Company, Danaher Corporation, Sigma-Aldrich Corporation, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., GE Healthcare, Merck KGAA, Olympus Corpopration, Perkinelmer, Inc., Promega Corporation. The global cell analysis market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Most of the players in the cell analysis instruments market are collaborating with companies and educational institutes in order to offer the products with better software also. The cell analysis market is expected to grow steadily in the forecast period. The major factor driving the growth is improved accuracy of cell imaging and analysis systems which in turn reduce time and cost of drug discovery process. In addition, the factors like increasing prevalence of cancer, getting help from the government bodies in the form of investments, funds and grants, improved informatics services, availability of better reagents and image analysis instruments are propelling the growth of the market. However, the major market restraints include enormous capital investments and shortage of skilled labor for high content screening procedure. The biggest opportunities for this market is the growing APAC market, high content screening services provided by CRO's, automation in cancer research for its early detection and reducing cost of the cancer treatment. Key Topics Covered: 1. Executive summary 2. Introduction 3. Market Analysis 4. Single cell analysis market by technology 5. Single cell analysis market by products 6. Single cell analysis market by field of study 7. Single cell analysis market by applications 8. Single cell analysis market by end users 9. Regional Market Analysis 10. Company Developments 11. Major Company Profiles - Agilent Technologies, Inc. - Beckton, Dickinson And Company - Danaher Corporation - GE Healthcare - Merck KGaA - Olympus Corpopration - Perkinelmer, Inc - Promega Corporation - Sigma-Aldrich Corporation - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/tj...ar_imaging
A: 41.13 (-0.24), SIAL: 137.16 (-0.01), DHR: 86.79 (-0.27)
Sigma-Aldrich Shareholders Clears Takeover by Merck KGaA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 11:40AM CST
Sigma-Aldrich's (SIAL) shareholders have approved its proposed acquisition by Germany's Merck KGaA for $17 billion.
ROC: 79.11 (-0.01), NL: 8.72 (+0.14), SIAL: 137.16 (-0.01), MTX: 71.84 (+0.11)
Sigma-Aldrich® Again Named Top Company for Strengthening Communities through Science
PR Newswire - Mon Dec 08, 7:30AM CST
Sigma-Aldrich Corporation (Nasdaq: SIAL) was named today to The Civic 50, an annual initiative that recognizes leading community-minded companies in the U.S. Conducted by Points of Light, the largest organization in the world dedicated to volunteer service, and supported by Bloomberg LP, The Civic 50 honors forward-thinking businesses that are strengthening their communities and demonstrating a correlation between civic engagement and overall bottom-line benefits.
SIAL: 137.16 (-0.01)
Sigma-Aldrich's stockholders grants approval for its USD140/share acquisition by Merck KGaA
M2 - Mon Dec 08, 6:59AM CST
Sigma-Aldrich (NASDAQ:SIAL) said on Friday that its stockholders have voted to adopt the merger agreement with and into Merck KGaA, Darmstadt, Germany at a special meeting of stockholders held earlier today.
SIAL: 137.16 (-0.01)
Global Glycobiology/Glycomics Market 2014-2019: Enzymes, Instruments, Kits, and Reagents
M2 - Mon Dec 08, 3:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/sj4p7d/glycobiologyglyco) has announced the addition of the "Glycobiology/Glycomics Market by Product, Application & by End User - Global Forecast to 2019" report to their offering. The key drivers for this market are the rising R&D expenditure by pharmaceutical and biotech companies, and increasing public and private funding for proteomics and glycomics research. According to the World Bank, funding for research and development activities in Asia was about $158.94 billion in 2001 and increased to $329.31 billion in 2010. Similarly, in the U.S., overall funding for research and development was about $291.77 billion in 2001, which increased to $428.94 billion in 2010. Increased funding activities are expected to positively impact the growth of the glycomics enzymes, instruments, kits, and reagents market. This report segment the global glycomics market by application, end users, products, and geographies. The application segments included in this report are diagnostics; drug discovery and development; immunology; oncology; and other applications. The end-user segments of this market are academic research institutes, contract research organizations, and pharmaceutical and biotechnology companies. The product segments included in this report are enzymes; instruments; kits; and reagents. Glycosidases; glycosyltransferases; neuraminidases; sialyltransferases; and other enzymes are subsegments of the enzymes product segment. Antibody arrays; HPLC; lectin arrays; MALDI-TOF; mass spectrometers; and other glycomics instruments are subsegments of the instruments product segment. Glycan labeling kits; glycan purification kits; glycan release kits; and other glycomics kits are subsegments of the kits market. Glycoproteins; monosaccharaides; oligosaccharides; and other glycomics reagents are subsegments of the reagents product segment. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Glycomics Market, By Product 8 Glycomics Market, By Application 9 Glycomics Market, By End User 10 Geographic Analysis 11 Competitive Landscape 12 Company Profiles - Agilent Technologies, Inc. - Bruker Corporation - Danaher Corporation - New England Biolabs - Prozyme - Shimadzu Corporation - Sigma-Aldrich Corporation - Takara Bio - Thermo Fisher Scientific - Waters Corporation For more information visit http://www.researchandmarkets.com/research/sj...ologyglyco
A: 41.13 (-0.24), SIAL: 137.16 (-0.01), DHR: 86.79 (-0.27), WAT: 114.54 (+0.21)
Sigma-Aldrich Stockholders Approve Acquisition By Merck KGaA
PR Newswire - Fri Dec 05, 11:30AM CST
Sigma-Aldrich Corporation (NASDAQ: SIAL) stockholders voted to adopt the previously announced merger agreement providing for the acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany at a special meeting of stockholders held earlier today. Sigma-Aldrich stockholders also approved, on an advisory, non-binding basis, compensation that may become payable to named executive officers as a result of the acquisition.
SIAL: 137.16 (-0.01)
Laboratory Filtration Market 2014-2019 - Global Technology, Product, Accessories & End-User Forecasts for the $2.5 Billion Market
M2 - Fri Dec 05, 3:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/hmsvk6/laboratory) has announced the addition of the "Laboratory Filtration Market by Technology, Product, Accessories & by End-User - Global Forecasts to 2019" report to their offering. The global laboratory filtration market is expected to grow at a strong CAGR during the forecast period of 2014-2019 and is estimated to be worth $2,532.6 million by 2019. The market is mainly driven by the increasing research activities in the pharmaceutical and biotechnology segments, and growing demand for biotech molecules for therapeutic and diagnostic applications and increasing purity requirements in end-user markets. However, technological developments cutting down the use of the membrane filtration technology may hamper the growth of the market to a certain extent. During the forecast period the microfiltration segment will continue to dominate the laboratory filtration market. Microfiltration segment is growing primarily due to increasing use of microfiltration membranes as prefilters to ultrafiltration and reverse osmosis processes. Furthermore, growing demand of filtration technologies in pharmaceutical and biopharmaceutical industries is also expected to drive the growth of the laboratory filtration market. By 2019, North America will be the largest share to the global laboratory filtration market, followed by Europe, Asia-Pacific, and RoW. Developed markets like North America and Europe are likely to grow at a lower CAGR as compared to the Asia-Pacific market. The Asia Pacific region is expected to have the fastest market growth during the forecast period, largely driven by the increasing research funding form government and private investors and growing number of research laboratories. The major players in the laboratory filtration market include The major players in the laboratory filtration market include Pall Corporation (U.S.), Merck Millipore (Germany), GE Healthcare (U.S.), Sartorius Group (Germany), 3M Purification (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Cantel Medical Corp. (U.S.), and Sigma Aldrich (U.S.). Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Global Laboratory Filtration Market, By Technology 8 Global Laboratory Filtration Equipment Market, By Type 9 Global Lab Filtration Accessories Market, By Type 10 Global Laboratory Filtration Market, By End User 11 Laboratory Filtration Market, By Geography 12 Competitive Landscape 13 Company Profiles - 3M Company - Cantel Medical Corp. - General Electric Company - Merck Millipore - Pall Corporation - Sartorius Group - Sigma-Aldrich Corporation - Sterlitech Corporation - Thermo Fisher Scientific, Inc. - Veolia Water Technologies Corporation For more information visit http://www.researchandmarkets.com/research/hmsvk6/laboratory
MMM: 166.96 (+0.09), GE: 25.83 (-0.05), PLL: 101.86 (+0.70), SIAL: 137.16 (-0.01), MRK: 57.46 (+0.25), CMN: 42.07 (+0.40)
Sigma-Aldrich Life Sciences Licenses Foundational CRISPR Patents from Broad Institute
PR Newswire - Thu Dec 04, 6:00AM CST
Sigma-Aldrich® Corporation (NASDAQ: SIAL), today announced that Sigma® Life Science, its innovative biological products and services business, has entered into a non-exclusive agreement for the use of CRISPR/Cas technology covered under patents held by the Broad Institute of MIT and Harvard. Under the agreement, Sigma-Aldrich is able to make, use and distribute the advanced gene editing tools for numerous research applications, including the generation of modified plant and animal models, custom cell line creation and for CRISPR/Cas arrayed and pooled genetic screening.
SIAL: 137.16 (-0.01)
Sigma-Aldrich Introduces Certified Reference Materials - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 10:40AM CST
Sigma-Aldrich Corporation (SIAL) announced that the Cerilliant brand, within its Applied Diagnostics and Testing division, has launched new solution-based Certified Reference Materials (CRMs) of seven Cannabis biomarkers.
NL: 8.72 (+0.14), SIAL: 137.16 (-0.01), TAM: 26.00 (+0.01), MTX: 71.84 (+0.11)
